30 At a median follow-up of 40 months, there was an almost significant decrease in mortality (HR 0.61, 95% CI 0.49–0.75) and failure-free survival (HR 0.31, 95% CI 0.26–0.37).
← all excerpts
Volume matters and intensification is needed: emerging trends in the management of advanced prostate cancer.
1
—
—